WELL Health Continues US Expansion with Proposed Acquisition of Majority Stake in WISP, a Rapidly Growing National Telehealth Leader Specializing in Women’s Health
- Silicon Valley based WISP is a leading national provider of telehealth and e-pharmacy solutions specializing in Women’s Health, delivering solutions for female reproductive and sexual health ailments to patients across all 50 states in the US.
- WISP has served more than 200,000 patients to date.
- WISP’s current annual revenue run-rate is approximately US$30 million(1) and represents greater than 100% YoY organic growth. WISP has gross margins exceeding 65% and achieved positive EBITDA over the last few quarters.
- WELL’s US$41 million control investment in WISP is fully funded via a combination of US$27.7 million in cash from treasury, US$6.2 million in WELL shares (issued at a price of $9.80/share) and includes a multi-year performance earnout up to a maximum of US$7.4 million.
WELL Health Technologies Corp. (WELL), a company focused on consolidating and modernizing clinical and digital assets within the healthcare sector, is pleased to announce it has entered into a definitive stock purchase agreement dated September 1, 2021 (the “Agreement“) with the shareholders of WISP, Inc. (“WISP“), a US technology leader and innovator in the delivery of quality telehealth and e-pharmacy experiences specializing in women’s health to acquire a majority of the issued and outstanding shares of WISP (the “Transaction“) for total a total transaction value of approximately US$41 million, which includes a future conditional earn-out of up to approximately US$7.4 million.
Recommended AI News: Ushur Forms AI Research Group to Power the Future of Customer Experience Automation
Hamed Shahbazi, Chairman and CEO of WELL commented, “Until recently, there has been a chronic under-supply of female focused healthcare services designed by female physicians, we know that the global women’s health market is a $30B+ industry growing at 6% annually. We are very pleased to report that this proposed transaction is expected to position WELL as an emerging provider of women’s health services in the United States and that we plan to leverage the impactful success and know-how of the WISP operations in the US to launch similar services in other countries, starting with Canada. WISP’s strong value proposition has filled a critical gap in women’s health which represents a large and growing opportunity for WELL.”
Matthew Swartz, founder and CEO of WISP commented, “WELL has a compelling history of growth, innovation and serving the underserved, and for this reason, we are thrilled to be joining the WELL family. Our patient centric online experience has provided care for hundreds of thousands of patients when they’ve needed support, and we look forward to continuing to rapidly scale our products and services to women and all humans, both in the United States and other countries starting in Canada.”
Dr. Laura Purdy, M.D. and WISP Medical Director states, “WISP started off by providing discreet herpes care and has grown to offer a comprehensive range of treatments including contraception delivery and primary care consultations. WISP’s core values of discretion, affordability, convenience, and immediacy has resonated with our customers. We are providing an appreciated service in a sex positive manner – sexual health is universal and nothing to be ashamed of.”
WISP Acquisition Highlights
With the proposed acquisition of WISP, WELL is building on its US telehealth presence, having previously entered the US market with the majority stake acquisition of Circle Medical. Combined with Circle Medical, WELL is approaching US$45 million in its current US-based telehealth revenue run-rate(1).
Founded in 2018, WISP has created a national telehealth and e-pharmacy presence, serving all 50 of the US states. WISP has served 200,000 patients to date, and offers both telehealth medical consultations, as well as prescription and natural medications. By offering discrete, timely access to treatments for ailments such as yeast infections, UTI’s, herpes, and other ailments related to sexual health, WISP has created a strong relationship with its customers, resulting in greater than 50% returning/subscription revenue, and NPS scores of 79. WISP has experienced strong, profitable revenue growth, with its current annualized run-rate of approximately US$30 million(1), representing over 100% year-over-year organic revenue growth. WISP’s rapidly growing digital revenue strengthens WELL’s digital portfolio and organic growth profile.
The combination of growing demand for e-pharmacy and virtual care services offers robust market tailwinds that the WISP platform is poised to benefit from. For instance, WISP operates in the online pharmacy industry that according to IBISWorld is anticipated to showcase 16% CAGR and reach over $60 billion on a global basis by 2025. Furthermore, telehealth services have seen a nearly 40x increase from pre-pandemic levels according to recent studies from McKinsey.
Recommended AI News: Riffyn Appoints Former Greenlots Executive, Vipul Doshi, as VP of Software Engineering
Under the terms of Agreement, the total consideration payable by WELL in connection with the Transaction is up to approximately US$41 million, which will be paid as follows: (i) approximately US$27.7 million in cash on the closing date; (ii) approximately US$6.2 million through the issuance of common shares in the capital of the Company on the closing date at a deemed issue price per share of $9.80 (the “Issue Price”); and (iii) a multi-year performance-based earn-out of up to approximately US$7.4 million, which is determined based on the WISP business maintaining its revenue performance post-closing. The Issue Price represents a 26.9% premium to the volume weighted average trading price (“VWAP“) of the Company’s common shares on the Toronto Stock Exchange (the “TSX“) for the fifteen trading days preceding the date of this announcement. If the VWAP of the Company’s common shares for the fifteen trading days preceding the closing date of the transaction is higher or lower than $7.72, then the number of common shares issuable on the closing date will be adjusted in direct inverse proportion to such difference in price. These consideration shares will be subject to certain volume based voluntary resale restrictions as provided in the Agreement.
It is expected that at the close of the Transaction, WELL will own approximately 53% of the issued and outstanding share capital of WISP on a fully diluted basis. The original securityholders of WISP, which includes the existing WISP senior management team, will mostly own the remaining balance of the shares of WISP and will continue to operate WISP on a post-closing basis. Pursuant to the terms of the Transaction, WELL shall have the right to acquire the remaining shares of WISP it does not already own as part of the Transaction pursuant to a call option.
Closing of the Transaction is expected to be completed in early Q4-2021 and is subject to a number of customary and other conditions, including receipt of requisite regulatory and exchange approvals.
D.A. Davidson is serving as WISP’s exclusive financial advisor and Goodwin Proctor LLP is acting as legal counsel to WISP. Dentons Canada LLP and Dentons US LLP are acting as legal counsel to WELL.
(1) Revenue run-rate refers to the annualized result of the last month’s revenue performance.
Recommended AI News: Mortgage Technology Leader Accurate Group partners with Novacap to Further Accelerate Growth
Comments are closed.